AU$200 - AusBiotech

31 OCT
2014
and save
Leading life science investors, analysts and advisors confirmed to speak include:
Jason Coloma
Global Head of Venture &
Innovation
Roche, Switzerland
Wen Cao
Principal of Shanghai Office
NTD Patent & Trademark
Agency, China
Dr Samantha Du
Chairman & CEO, Zai
Laboratory; Venture Partner,
Sequoia Capital, China
Barry Palte
Executive Deputy Chairman
Bluemount Capital,
Australia
Dr Richard M Soll
Senior Vice President,
International Discovery
Service Unit
WuXi AppTec, China
Dr Dan Zhang
CEO
Fountain Medical, China
Ben Borson
Founder and President
Borson Law Group, United
States
James Posnett
Manager Listings Business
Development
ASX, Australia
Peter Soelberg
Managing Director –
Australasia
Novo Nordisk, Australia
Knowledge Partner:
Lanyard Sponsor:
Supporting Partner:
What’s new in 2014?
Networking Sponsor:
Silver Sponsor:
•Additional spaces made available to biotech
companies to present their pipelines
•Well designed program, to allow for the right
balance of keynote speakers, panel discussions, and
company presentations
•Additional biopartnering meeting sessions
Reasons to Attend:
To register, www.AusBiotechInvest.com/registration or contact Beacon Events at +852 2219 0111 or email to [email protected]
Registration
•Hear the pipeline of at least 30 Australian Biotech
companies, as well as 5-10 international companies
•Take part in fruitful discussions through the
biopartnering system
•Listen to expert panellists and keynote speakers discuss
the trends and opportunities in biotech currently
•Liaise and network with investors, pharma
representatives, and biotech companies
•Be a part of one of the most important events on
the life sciences calendar
2013 Attended
Investors
Scott Power
Senior Analyst Healthcare &
Biotechnology
Morgans, Australia
Conference
Day Two
Dr Sofie Qiao
Managing Director, WuXi
Venture Fund
WuXi AppTec, China
Presenting life science companies
include:
Conference
Day One
Philip Dreyfuss
Analyst
Farallon Capital
Management, United States
Introduction
AU$200
3-4 December 2014; Crown Conference Centre, Melbourne
State Host Sponsor:
Register by
Overview
AUSTRALIA
Co-organisers:
Delegate profile of 2013 event:
by Company Type:
Why attend Australia Biotech Invest 2014?
5.0%
16.9%
3.3%
2.0%
7.0%
0.3%
42.9%
4.0%
1.0%
8.0%
1.3%
0.7%
7.0%
0.7%
“After a good experience in Hong Kong at Asia Biotech Invest
we went to Australia Biotech Invest hoping for the same. We
were wrong! It far exceeded expectations and we are following
up with four potential investor groups - keep it up Ausbiotech!”
Brad Walsh, CEO, Minomic International
“Having all the attendees in a closed location meant it was
easy to locate and converse with investors and fellow Biotech
colleagues. The booth concept was a winner.”
Nick Ede, Executive Director, Imugene
•Family offices
Eric N. Shiozaki, Director, Apposite Capital
Who Should Attend?
•Institutional investors
•Private equity investors
•Venture capitalists
•Fund managers
4.6%
8.6%
20.5%
5.0%
15.2%
4.0%
3.0%
4.3%
34.8%
Conference
Day Two
•Angel investors
“The Ausbiotech Biotech Invest 2013 and Ausbiotech 2013
conferences were informative, dynamic and productive. The
panel format and discussion topics at Ausbiotech Biotech
Invest 2013 were particularly constructive. They facilitated
engaging dialogue during which regional and industry-specific
issues were openly discussed. As an investor, I was particularly
impressed with the range of participating stakeholders from the
investment and start-up biotech communities. Ausbiotech 2013
provided a great platform for all industry stakeholders, ranging
from entrepreneurs to large pharma management, and local
academics to international investors.”
Conference
Day One
by Job Function:
Analyst
BD / Marketing
C-Level
Consultant
Investment Management
Media
Others
Regulatory
Senior Management
Introduction
Academic / Association
Biotech
CMO / CRO
Communication Strategies
Government
Hospital
Investor
Media
Others
Pharma
Research Institute
Science Park
Services
Stock Exchange
In 2014, the program will feature at least 40 biotech company
presentations, including 5 - 10 international companies.
The program will also feature a mix of expert panellists, and
keynote speakers from across the world.
Attendance at the event allows delegates, investors and
companies the opportunity to use the biopartnering system.
This provides individuals and companies the chance to prearrange one-on-one meetings to take place during the event.
In previous years, this system has been responsible for many
fruitful discussions, which have lead to deals taking place
between investors and biotech companies.
What delegates have said about the 2013
event:
Overview
Australia Biotech Invest, jointly organised by AusBiotech and
Beacon Events, brings together life science investors with
biotech innovators from Australia, and worldwide. The event
series, run twice yearly in both Melbourne, Australia, and Hong
Kong, provides the perfect opportunity for biotech companies
to present their pipeline to a room full of bone fide investors.
by Countries / Regions:
•Major pharmaceutical companies
•Brokerage firms
•Stock exchanges
•Consultants
Australia / New Zealnd
Asia
Europe
North America
88.4%
5.3%
2.6%
3.6%
2013 Attended
Investors
•Investment banks
•Analysts
•Law firms
Plus: Biotech companies looking for funding or partners
For presenting, sponsorship and exhibition opportunities, please contact
(Australia/New Zealand) Amelia Lundstrom: [email protected] | (Rest of World) King Tai: [email protected] or Shahid Shaikh: [email protected]
Registration
•CMOs and CROs
Registration and morning coffee
09:15
WELCOME & OFFICIAL OPENING
Glenn Cross, Chief Operating Officer, AusBiotech
09:25
Conference chairman’s opening remarks and business
card exchange
Joshua Funder, Partner, GBS Venture Partners
09:30
KEYNOTE: Global investment trends and opportunities
• Biotech investment trends, opportunities and business
models for future growth
Philip Dreyfuss, Analyst, Farallon Capital Management,
United States
09:45
KEYNOTE: Overview of biotech investment in Asia
• Investment trends and opportunities in biotech and life
sciences in Asia
10:00
Biotech Company Spotlight Presentations
Megan Baldwin, Managing Director & CEO, Circadian
Julie Phillips, Chief Executive Officer, Biodiem
Nick Ede, Executive Director, Imugene
Dr John Chiplin, Chief Executive Officer, Polynoma
Mark Rowlands, Vice President Business Development, IDT Australia
Lawrence LaPointe, Chief Executive Officer, Clinical Genomics
Technologies
Simon Wilkinson, Director & CEO, Innate Immunotherapeutics
Lunch and networking with exhibitors & investors and
1-on-1 meetings
14:30
PANEL: Maximising your after tax return on investment in
Australia – strategies and opportunities
• Tax and financial structures for start-ups in order to leverage
the R&D incentive
• Current “state of play” of the R&D tax incentives and
grants available
• Understanding the Australian Manufacturing Incentive
scheme and how can Biotechs enhance their access to these
financial grants?
Moderator:
Joshua Funder, Partner, GBS Venture Partners
Panellists:
David Wilson, General Manager, R&D Tax Incentive, AusIndustry
– Entrepreneur Development, Department of Industry
Biotech Company Spotlight Presentations
Dr Greg Collier, Chief Executive Officer, Invion
Dr Marie Roskrow, Chief Financial Officer, Patrys
Robert Mair, Chief Executive Officer, Fitgenes
Geoff Daly, Chief Executive Officer, Analytica
Dr Deborah Rathjen, CEO & Managing Director, Bionomics
Morning tea, networking with exhibitors & investors and
1-on-1 meetings
15:00
16:30
PANEL: Growing biotech business through international
partnering & licensing
• Global trends in international partnering and licensing:
examining successful partnership models
• What do big pharma look for in a biotech partner?
• Partnerships key challenges and opportunities
Moderator:
Joshua Funder, Partner, GBS Venture Partners
Panellists:
Peter Soelberg, Managing Director – Australasia, Novo Nordisk
Pharmaceuticals
Jason Coloma, Global Head of Venture & Innovation, Roche
Yinxiang Wang, CEO and Chief Scientistic Officer, Betta
Pharmaceuticals
17:00
Networking Reception
Sponsored by
Supporting Associations:
Biotechnologie-Industrie-Organisation Deutschland e. V.
Supporting Organisations:
To register, www.AusBiotechInvest.com/registration or contact Beacon Events at +852 2219 0111 or email to [email protected]
Registration
Biotech Company Spotlight Presentations
Lusia Guthrie, CEO & Managing Director, LBT Innovations
Prof Larry Ming-cheung Chow, Department of Applied Biology
and Chemical Technology, The Hong Kong Polytechnic
University
Andrew Ronchi, CEO, DorsaVi
Afternoon tea and networking with exhibitors & investors
and 1-on-1 meetings
2013 Attended
Investors
13:45
16:00
Conference
Day Two
11:30
12:45
PANEL: Assessing Biotech drivers and performance in
Australia and New Zealand: What can Biotechs do to better
access capital from these lucrative capital markets?
• Assessing stock performance across key exchanges
• Spotlight on recent listings and outlook for IPOs
• Which stocks are on the analysts’ watch list, and why?
Moderator
George Syrmalis, CEO & Executive Chair, IQX Investment Labs
Panellists:
Scott Power, Senior Analyst Healthcare & Biotechnology,
Morgans, Australia
James Posnett, Manager Listings Business Development, ASX
Steven Yatomi-Clarke, Director, Corporate Finance,
Patersons Securities
Dr Graeme Wald, Investment Director, Bioscience Managers
Conference
Day One
10:30
PANEL: International investor panel: what’s hot in life
sciences
• Long term investment outlook for biotech from
investors’ perspective
• The future of biotech: key challenges and opportunities
• What’s hot in life sciences and where is the money
being invested
Moderator:
Joshua Funder, Partner, GBS Venture Partners
Panellists:
Dr Sofie Qiao, Managing Director, WuXi Venture Fund, WuXi
AppTec, China
Robin Davison, Director of Healthcare, Edison Investment
Research, United Kingdom
12:00
Introduction
08:30
Overview
DAY ONE – Wednesday 3 December 2014
Conference chairman’s opening remarks and day one recap
Matt McNamara, Chief Investment Officer, BioScience Managers
09:10
KEYNOTE: Why resource sector investors look at biotech
Brian Leedman, Branch Chair, AusBiotech
09:30
PANEL: Resource investors
• The link between the risk and return of small mining
companies and companies in the biotech sector
• Shift in investor capital from small resources to biotech
Moderator:
Glenn Cross, Chief Operating Officer, AusBiotech
Panellists:
Brian Leedman, Branch Chair, AusBiotech
Richard Hopkins, Chief Executive Officer, Phylogica
Anton Uvarov, PhD, Healthcare Analyst, Forrest Capital
Mike Munro, Investment Broker, Hartleys
10:00
Biotech Company Spotlight Presentations
11:00
Morning tea, networking with exhibitors & investors and
1-on-1 meetings
11:30
KEYNOTE: An update on investment opportunities in Victoria
• Views on the essential elements that make Melbourne a place
to invest for biotech
Cameron Boardman, Executive Director – Innovation, Technology
& Industry Programs, Department of State Development,
Business & Innovation
12:00
Biotech Company Spotlight Presentations
13:00
Lunch and networking with exhibitors & investors and 1-on-1
meetings
Biotech Company Spotlight Presentations
15:00
KEYNOTE: The rapidly evolving healthcare investment
landscape in Greater China
• Current developments in China’s biotech and medtech sector
• Outlook for China’s healthcare market for 2015 and beyond and
expected impact on investment opportunities in the sector
• The state of VC investment
Wen Cao, Principal of Shanghai Office, NTD Patent & Trademark
Agency, China
17:00
Exhibition Floor plan:
Conference Hall
Registration
2013 Attended
Investors
14:00
15:45
16:35
PANEL: Building win-win partnerships in China
• What do investors in Asia look for when investing into
biotech companies? What types of companies at what stage
are most favoured?
• How can biotech companies best position themselves to
attract capital and/or set up partnerships in Asia?
• Accessing funding and grants and collaborating across
borders
Moderator:
Matt McNamara, Chief Investment Officer, BioScience Managers
Panellists:
Dr Samantha Du, Chairman & CEO, Zai Laboratory; Venture
Partner, Sequoia Capital, China
Barry Palte, Executive Deputy Chairman, Bluemount Capital,
Australia
Dr Richard M Soll, Senior Vice President, International Discovery
Service Unit, WuXi AppTec, China
Dr Dan Zhang, CEO, Fountain Medical, China
Benjamin Borson, Founder and President, Borson Law Group,
United States
Hao Zhou, Director and head of China Healthcare, China
Renaissance Group
Biotech Company Spotlight Presentations
CLOSING PANEL
Key challenges and investment opportunities for biotech in
coming 5 years
• Key challenges and opportunities for biotech investment
and innovation going forward and will biotech live up to its
potential?
Moderator:
Matt McNamara, Chief Investment Officer, BioScience Managers
Chairman’s closing remarks
Conference
Day Two
09:00
15:15
Conference
Day One
Registration and morning coffee
Introduction
08:30
Overview
DAY TWO – Thursday 4 December 2014
Media Partners:
Registration
For presenting, sponsorship and exhibition opportunities, please contact
(Australia/New Zealand) Amelia Lundstrom: [email protected] | (Rest of World) King Tai: [email protected] or Shahid Shaikh: [email protected]
Sponsoring or exhibiting at the Biotech Invest conferences
provides a unique opportunity to promote your company to the
assembled audience of investors and life science experts. We
offer tailored sponsorship opportunities designed to meet your
specific marketing needs.
Take an exhibition booth and one of the limited high-profile
company spotlight slots on the agenda to showcase your
projects and investment opportunities to the investors and
potential JV partners at the event.
Pharma companies:
Service providers, law firms and industry consultants:
Consider taking up the Knowledge Partner package to showcase
your thought leadership to the biotech companies, big pharma
representatives and life science investors attending the event.
Australia / New Zealand
Amelia Lundstrom
T: +61 3 9828 1435
E: [email protected]
•RBS Morgans
•Afandin
•Goldman Sachs
•Scientia Capital
•AFG Venture Group
•Grannus Securities
•Alex Cowie
•Hawkesbury Partners
•Self-Managed Super Funds Professionals
Association of Australia
•Anchor Advisory
•Hirst Shabian & Hirst Advisory & Investment
Services
•Apposite Capital
•Aqua Capital
•Atwill Consulting
•Baillieu Holst
•Baker Young Stockbrokers
•Bartov Enterprises
•Beconwood Securities
•Bergen Capital
•Bio Innovation
•BioPacificVentures
•Bioscience Managers
•Bluehawk Capital
•Brandon Capital Partners
•Calpain Therapeutics
•Canterbury Funds Management
•China BlueSky Ventures
•CIMB Securities
•Cooper Investors
•CSIRO - Materials Science & Engineering
•Cure Kids Ventures
•Dazane
•Dewver
•Duce Investments
•E.L. & C. Baillieu Stockbroking
•EcoR1 Capital Fund
•Edison Investment Research
•EWave
•Fairview Equity Partners
•Farego Enterprise
•Fitzroy Capital
•Fortrend Securities
•Somerset Capital
•IFM Investors
•Starfish Ventures
•Innovation Capital
•Strategic Management
•IQX Ltd Janssen-Cilag
•Szabo Trading
•JDG
•Talu Ventures
•Jevons Global
•Terrain Capital
•JM Financial Group
•Thomas Hannaford
•Kamara Poulos Group - KPG
•Trans Tasman Commercialisation Fund - TTCF
•Kinetic Investment Partners
•Uniseed Ventures
•Lion Capital
•VAGO- Victorian Auditor-Generals Office
•Lodge Partners
•Veritas Securities
•Macquarie Capital
•Walravens Family Super fund
•Macquarie Private Wealth
•Magna Group Capital Management
•MedImmune Ventures
•Merck Sharp & Dohme
•Milford Asset Management
Job Function - Investor:
•Morgans Financial
•Newcontent
•Obi-Wan Investments
•OrbiMed
•Oxford Capital
•PAC Partners
•Patersons Securities
•Peloton Capital
•pharmaBank
•PharmaVentures
•PhillipCapital
•Platinum Road
•Prime Value Asset Management
•Private Investor
•Private Portfolio Managers
Analyst
BD / Marketing
C-Level
Investment Management
Senior Management
For presenting, sponsorship and exhibition opportunities, please contact
(Australia/New Zealand) Amelia Lundstrom: [email protected] | (Rest of World) King Tai: [email protected] or Shahid Shaikh: [email protected]
10.9%
1.6%
9.3%
34.1%
44.2%
Registration
•Fenex Capital Management
•Shire Australia
2013 Attended
Investors
Rest of the World
King Tai
Shahid Shaikh
T: +852 2531 6125
T: +852 2531 6218
E: [email protected]: [email protected]
•QIC
•GE
Conference
Day Two
Contact us to find out how you can participate in the Australia
Biotech Invest 2014.
•GBS Venture Partners
•Acuity Capital
Conference
Day One
Take up one of the limited high-profile company presentation
slots on the agenda to highlight your licensing and partnering
opportunities to the biotech entrepreneurs attending the
event.
•90 West Asset Management
Introduction
Biotech companies:
Investors attending the 2013 event included:
Overview
Why Sponsor Biotech Invest?
2014
Click here to
submit form via email
Phone
+ 852 2219 0111
Email
[email protected]
Fax
+852 2219 0112
Mail: Beacon Events Limited
20/F Siu On Centre, 188 Lockhart Road,
Wanchai, Hong Kong
3-4 December 2014 • Crown Conference Centre, Melbourne
Register & pay by 31 October 2014
Standard rate
Venue Information
Thereafter
Fee
GST
Total
Fee
GST
Total
AU$ 2,045
Save AU$200
AU$ 204.5
AU$ 2,249.5
AU$ 2,245
AU$ 224.5
AU$ 2,469.5
Fee
GST
Total
Fee
GST
Total
Member of supporting associations / organisations*
AU$ 1,545
Save AU$200
AU$ 154.5
AU$ 1,699.5
AU$1,745
AU$ 174.5
AU$ 1,919.5
Non-member
AU$ 1,745
Save AU$200
AU$ 174.5
AU$ 1,919.5
AU$1,945
AU$ 194.5
AU$ 2,139.5
2 day conference
Pharma / Biotech Companies / CRO's
Association/Organisation:______________________________________________________________________ Membership Number:______________________________________
Academics / Tech Transfer Officers
Full-time staff / student of a nonprofit university,
hospital, institute**
Fee
GST
Total
Fee
GST
Total
AU$1,145
AU$ 114.5
AU$ 1,259.5
AU$1,145
AU$ 114.5
AU$ 1,259.5
Room rate from AUD 280.00
Click here to book a room.
Payment Details (Tick one only)
Accept enclosed cheque made payable to Resourceful Australia Pty Ltd
Please invoice me
Credit Card
Card Type:
Institution:_______________________________________________________________________________ Staff/Student ID Number:______________________________________
Card No.
Conference
Day Two
**Delegate must register with an email address that correlates to the institution stated in the Company / Organisation field on the registration form.
**Delegate is required to provide a staff or student ID number showing that s/he is at the stated institution to qualify for the Academics rate.
Cardholder’s Name
Your Details (Please use BLOCK LETTERS)
Cardholder’s Signature
(Mr/Mrs/Ms/Miss/Dr) First Name Last Name
Job Title Department
Direct Tel Mobile
Email Direct Fax
Conference
Day One
*Member rates are available to members of a supporting association or organisation. Delegate is required to provide the member registration code and membership details to register
with discounts.
Crown Conference Centre, Melbourne, Australia
8 Whiteman Street, Southbank
Introduction
PROMO CODE:
BA799MM
WEB
PROMO
CODE:
BH793MM TSPH
I will attend at the following rate (please P the appropriate box)
Overview
AUSTRALIA
Yes, I would like to receive information on future events via email. By giving you my email address. I am giving only the organisers the permission to contact me by email.
Your Company Details
Company Name
Business Nature
Address
City Last Name
Title Department
No. of Employees
State Postcode Country
Expiry Date (mm/yy)
Security Code (CVV2):
Payment Amount
Date
2013 Attended
Investors
Approving Manager
(Mr/Mrs/Ms/Miss/Dr) First Name Job Title
Terms & Conditions*
I acknowledge and accept these terms and conditions
Print Name
Signature
To register, www.AusBiotechInvest.com/registration or contact Beacon Events at +852 2219 0111 or email to [email protected]
Registration
All discount can only be applied at the time of registration and discount cannot be combined. In the event that more than one discount is applicable, delegates will receive the discount with the highest value. All discounts are subject to approval. Please note the conference fee does not include travel or hotel accommodation costs.
1.Should you be unable to attend, a substitute delegate is always welcome at no extra charge. 2. Alternatively, the organisers can also provide a credit note for attendance one of the future events by Beacon Events within Asia Region (Except Mines and Money Series and IMARC) for cancellations received 14 days prior to the event. Alternatively, a 50%
refund will be provided for cancellations received in writing (letter or facsimile) no later than four weeks prior to the event; thereafter we regret no refunds or credit note can be arranged. 3. Beacon Events Ltd reserve the right to alter the programme without notice including the substitution, alternation or cancellation of speakers and / or topics and / or
alternation of the dates and / or location of the event. 4. The organisers are not responsible for any loss or damage as a result of a substitution, alternation, postponement or cancellation of any event. ©2014 Beacon Events Ltd. All rights reserved.